Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
スポンサーリンク
概要
- 論文の詳細を見る
- 1998-08-07
著者
-
Loos W
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
De Jonge
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
Loos Walter
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
Verweij J
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
Verweij Jaap
Laboratory Of Translational And Molecular Pharmacology Department Of Medical Oncology Erasmus Univer
-
DE BRUIJN
Department of Medical Oncology, Erasmus MC-University Medical Center Rotterdam
-
SPARREBOOM Alex
Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam
-
DE BRUIJN
Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam
-
STOTER Gerrit
Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam
-
NOOTER Kees
Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam
-
Sparreboom A
Clinical Pharmacology Research Core Medical Oncology Branch Center For Cancer Research National Canc
-
Nooter Kees
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
De Bruijn
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
-
Stoter Gerrit
Laboratory Of Experimental Chemotherapy And Pharmacology Department Of Medical Oncology Rotterdam Ca
関連論文
- Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry
- Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry
- Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry
- Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry
- Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection
- Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection
- O^6 -Methylguanine-DNA Methyltransferase (MGMT) as a Determinant of Resistance to Camptothecin Derivatives
- Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection
- Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces
- Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
- Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
- Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography
- Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism
- Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices